Visit COVID-19 resources

[Skip to Content]

Clinical Guidance

Response to NICE announcing their positive draft guidance for Eylea® for the treatment of macular oedema secondary to CRVO

Jan 06

College Statement The Royal College of Ophthalmologists welcomes the Final Appraisal Determination (FAD) from NICE recommending Eylea® (aflibercept) as a treatment option for visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO). We hope that this decision will help the clinical commissioning groups to support the rapid implementation of the final

  • 6 January 2014

MHRA Drug Safety Update Risperidone & paliperidone:risk of intraoperative floppy iris syndrome in patients undergoing cataract surgery

Dec 02

The Medicines and Healthcare Products Regulatory Agency has issued a Drug Safety Update to alert medical professionals to cases of intraoperative floppy iris syndrome (IFIS) during cataract surgery  reported in patients taking the atypical antipsychotics risperidone or paliperidone. IFIS may increase the risk of eye complications during and after cataract surgery Risperidone & paliperidone:risk of

  • 2 December 2013

NICE rapid review of the use of fluocinolone acetonide for chronic DMO

Oct 01

College Statment Since the release of TA 2711 in January 2013, NICE has undertaken a rapid review of the use of fluocinolone acetonide for chronic diabetic macular oedema2 and has recently released the FAD document for this single technology appraisal3. In the FAD document, the following guidance has been issued: Fluocinolone acetonide intravitreal implant is

  • 1 October 2013

NICE guidance on Ocriplasmin

Sep 17

College Statement Ocriplasmin is a recombinant protease enzyme that is effective in lysing fibronectin and laminin bonds at the vitreoretinal interface thus relieving vitreoretinal traction following intravitreal injection. Pivotal phase III trials have shown its effectiveness in treating vitreomacular traction leading to European Union approval in March 2013. The Royal College of Ophthalmologists welcomes the

  • 17 September 2013

Preservative free (PF) Trusopt® (dorzolamide hydrochloride) eye drops

May 13

MSD has informed the Royal College of Ophthalmologists that there are now a limited number of preservative-free (PF) Trusopt® (dorzolamide hydrochloride) eye drops presently available in the UK. In light of this and the fact that it is a limited supply, The College would like to advise you of the recommended best use of this

  • 13 May 2013